daxor.com (DXR) - חוב לטווח ארוך להון

Daxor Corporation is expanding sales of its blood analysis systems through government procurement while avoiding mergers. Growth is driven by lobbying and strict FDA oversight. The long-term debt-to-equity ratio provided by the GURU.Markets system confirms stability, where the 0.00 mark characterizes this parameter. The monopoly position of DXR is secured by patents on radioisotope methods, which preclude the emergence of direct competitors.

This metric measures the proportion of long-term liabilities within the equity structure, determining the company's degree of financial leverage. Investors utilize it to assess debt sustainability and bankruptcy risks when comparing issuers. The current long-term debt-to-net assets ratio stands at 0.00. Low borrowing levels minimize the payment burden, which is critically important for Daxor Corporation (DXR), as its growth rates are constrained by the conservatism of the healthcare market and reductions in government budgets.